Subscribe to Search results

The Trent Regional Transfusion Centre encouraged the use of blood ordering schedules in local hospitals.

Published on:

Dr William Wagstaff tried to persuade haemophilia clinicians to revert to cryoprecipitate and keep away from commercial products as a result of HIV/AIDS.

Published on:

Dr William Wagstaff gave oral evidence to the Inquiry that if his regional transfusion centre had been asked to increase the production of cryoprecipitate at the centre, they would have been able to do so quickly.

Published on:

The Trent Regional Transfusion Centre kept a separate database of HIV donors and hepatitis donors. They also provided this information to the Centre for Disease Surveillance and Control.

Published on:

The Trent Regional Transfusion Centre kept samples of any donation sent to the Blood Products Laboratory for a year at the Laboratory's insistence, and for other donations, for a number of months in case there was a report of hepatitis.

Published on:

According to Dr William Wagstaff's evidence to the Inquiry, during a discussion on AIDS at a regional transfusion directors meeting, there was a consensus on discontinuing sessions in areas of high-risk donors, but the option of questioning donors at sessions was more contentious.

Published on:

Dr William Wagstaff began sending out the Department of Health and Social Security's AIDS leaflet to donors with call-up cards and handing them out at sessions.

Published on:

Dr Frank Boulton gave oral evidence to the Inquiry that it was part of his job to go round the hospitals, talking to the consultants and the laboratory staff as well encouraging them to cut down on the use of blood for the benefit of the patients.

Published on:

According to Dr Vanessa Martlew's evidence to the Inquiry, the regional transfusion centre in Merseyside played a role in auditing the use of blood in their hospitals.

Published on:

Professor Contreras educated clinicians about the responsible and ethical use of blood and organised meetings on transfusion-transmitted infections.

Published on:

Scottish National Blood Transfusion Service directors recommended that regional transfusion centres accept formal responsibility for encouraging good practice in the hospital blood banks they supplied.

Published on:

According to Dr Gamal Gabra's recollection, Dr John Wallace started early attempts to achieve self-sufficiency in Scotland by introducing the concept of reducing the use of whole blood transfusion and promoting the use of components instead.

Published on:

Professor Stanislaw Urbaniak set up a Hospital Transfusion Committee in the Aberdeen Royal Infirmary to monitor usage and compliance with maximum surgical blood ordering schedules for each operation and procedure that might require a transfusion.

Published on:

Regional transfusion centres kept the records of donors who tested positive for HIV and hepatitis separately from their other records, to ensure their confidentiality.

Published on:

In a letter to colleagues, Dr Charles Bowley sought to make a case for using better quality cryoprecipitate instead of imported factor concentrates.

Published on:

Donor eligibility was established by a qualified clerk asking pre-prepared questions in the presence of a medical officer.

Published on:

Regional transfusion directors were asked to increase their production of cryoprecipitate as a much lower risk product.

Published on:

Dr John Cash published an article in The British Medical Journal entitled "Haemophilia A and the blood transfusion service: a Scottish study". The article stated that cryoprecipitate was suitable for home treatment.

Published on:

At a meeting of directors of the Scottish National Blood Transfusion Service and haemophilia directors, Dr Cash "emphasised the important part cryoprecipitate could play in haemophilia treatment" and urged for "serious consideration of the use of cryoprecipitate for" home treatment. Haemophilia directors were reported as "generally not in favour of using cryoprecipitate in this way".

Published on:

In a meeting of the Haemophilia and Blood Transfusion Working Group, Dr Cash raised concerns about the amount of commercial product being used.

Published on: